David Budd, CEO of genedrive plc (Manchester, UK), underscores the emerging role of pharmacogenetics testing in patient safety and treatment efficacy for those with genetic variants modifying their response to certain drug treatments.
What once seemed plausible only in science fiction – analyzing the building blocks of human design – is now a reality that can be accomplished at a patient’s bedside in less than half an hour. Imagine the profound impact of replacing an ineffective medication with a better-suited one in the treatment of those resistant to the intended effects?
[ui-btn url=”https://www.neuro-central.com/the-burgeoning-role-of-pharmacogenetics-testing-the-future-of-personalized-medicine/” text=”READ MORE ON NEURO CENTRAL NOW” target=”_blank”][/ui-btn]
The post The burgeoning role of pharmacogenetics testing: the future of personalized medicine appeared first on BioTechniques.
Powered by WPeMatico